238 related articles for article (PubMed ID: 21079767)
1. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.
Pretorius C; Stover J; Bollinger L; Bacaër N; Williams B
PLoS One; 2010 Nov; 5(11):e13646. PubMed ID: 21079767
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar SS; Grant PM; Bendavid E
BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
[TBL] [Abstract][Full Text] [Related]
5. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
6. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
[TBL] [Abstract][Full Text] [Related]
8. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
[TBL] [Abstract][Full Text] [Related]
9. The impact of prevention-effective PrEP use on HIV incidence: a mathematical modelling study.
Roberts DA; Bridenbecker D; Haberer JE; Barnabas RV; Akullian A
J Int AIDS Soc; 2022 Nov; 25(11):e26034. PubMed ID: 36385504
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
[TBL] [Abstract][Full Text] [Related]
11. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis.
Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P
J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874
[TBL] [Abstract][Full Text] [Related]
12. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
[TBL] [Abstract][Full Text] [Related]
13. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.
Hallett TB; Baeten JM; Heffron R; Barnabas R; de Bruyn G; Cremin Í; Delany S; Garnett GP; Gray G; Johnson L; McIntyre J; Rees H; Celum C
PLoS Med; 2011 Nov; 8(11):e1001123. PubMed ID: 22110407
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
[TBL] [Abstract][Full Text] [Related]
15. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.
Walensky RP; Jacobsen MM; Bekker LG; Parker RA; Wood R; Resch SC; Horstman NK; Freedberg KA; Paltiel AD
J Infect Dis; 2016 May; 213(10):1523-31. PubMed ID: 26681778
[TBL] [Abstract][Full Text] [Related]
16. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
[TBL] [Abstract][Full Text] [Related]
17. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
[TBL] [Abstract][Full Text] [Related]
19. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
[TBL] [Abstract][Full Text] [Related]
20. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
Gomez GB; Borquez A; Case KK; Wheelock A; Vassall A; Hankins C
PLoS Med; 2013; 10(3):e1001401. PubMed ID: 23554579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
